{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T07:07:49Z","timestamp":1792825669414,"version":"4.5.0"},"reference-count":22,"publisher":"BMJ","issue":"7","license":[{"start":{"date-parts":[[2025,2,6]],"date-time":"2025-02-06T00:00:00Z","timestamp":1738800000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Ministry of Science and ICT, Republic of Korea","award":["RS-2024-00348451"],"award-info":[{"award-number":["RS-2024-00348451"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Neurol Neurosurg Psychiatry"],"accepted":{"date-parts":[[2025,1,1]]},"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Reliable biomarkers are essential for predicting the progression speed and prognosis of patients with amyotrophic lateral sclerosis (ALS). We previously identified NCK-associated protein 1 (NCKAP1) as a critical factor in the defective phagocytosis observed in induced microglia-like cells (iMGs) from patients with rapidly progressive sporadic ALS. This study explored the roles of microRNA (miRNA)-214, which targets the<jats:italic>NCKAP1<\/jats:italic>gene, in the progression of ALS.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>The discovery cohort (n=29) was used to identify miR-214 targeting<jats:italic>NCKAP1<\/jats:italic>genes. The validation cohort (n=132) was used to determine the clinical usability of miR-214 for predicting disease progression speed and survival time.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>In the discovery cohort, miR-214 levels were increased in plasma and iMGs from rapidly progressive ALS participants. This finding was validated in another cohort of 132 ALS participants and 30 age-matched healthy volunteers. Plasma miR-214 levels correlated with disease progression, severity and survival, distinguishing between rapidly progressive and slowly progressive ALS. In addition, miR-214 levels also correlated with plasma neurofilament light chain (NfL) and cerebrospinal fluid inflammatory cytokines, showing specific associations with increased NfL and monocyte chemoattractant protein 1 (MCP-1). Survival prediction accuracy improved when miR-214 levels were considered with NfL or MCP-1 levels.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Plasma miRNA-214 could serve as a novel biomarker for predicting the progression and prognosis of ALS.<\/jats:p><\/jats:sec>","DOI":"10.1136\/jnnp-2024-335177","type":"journal-article","created":{"date-parts":[[2025,2,6]],"date-time":"2025-02-06T18:21:39Z","timestamp":1738866099000},"page":"716-720","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":7,"title":["miRNA-214 to predict progression and survival in ALS"],"prefix":"10.1136","volume":"96","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2746-0686","authenticated-orcid":false,"given":"Min-Young","family":"Noh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min-Soo","family":"Kwon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6011-629X","authenticated-orcid":false,"given":"Ki-wook","family":"Oh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minyeop","family":"Nahm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinseok","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hee Kyung","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae-sung","family":"Bae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bugyeong","family":"Son","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9644-9598","authenticated-orcid":false,"given":"Seung Hyun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,2,6]]},"reference":[{"key":"2025061300350681000_96.7.716.1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)60944-1"},{"key":"2025061300350681000_96.7.716.2","doi-asserted-by":"crossref","DOI":"10.1186\/s13024-023-00685-6","article-title":"Fluid biomarkers for amyotrophic lateral sclerosis: a review","volume":"19","author":"Irwin","year":"2024","journal-title":"Mol Neurodegener"},{"key":"2025061300350681000_96.7.716.3","first-page":"e1610","article-title":"Revised Airlie House consensus guidelines for design and implementation of ALS clinical trials","volume":"92","author":"van den Berg","year":"2019","journal-title":"Neurology (ECronicon)"},{"key":"2025061300350681000_96.7.716.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.trecan.2016.10.013"},{"key":"2025061300350681000_96.7.716.5","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2021.101063","article-title":"The current landscape of the FDA approved companion diagnostics","volume":"14","author":"J\u00f8rgensen","year":"2021","journal-title":"Transl Oncol"},{"key":"2025061300350681000_96.7.716.6","unstructured":"U.S. Food and Drug Administration . About FDA\u2019s biomarker qualification program. 2018."},{"key":"2025061300350681000_96.7.716.7","doi-asserted-by":"publisher","DOI":"10.1002\/ana.25302"},{"key":"2025061300350681000_96.7.716.8","doi-asserted-by":"crossref","DOI":"10.1038\/s41392-023-01588-0","article-title":"Microglia in neurodegenerative diseases: mechanism and potential therapeutic targets","volume":"8","author":"Gao","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"2025061300350681000_96.7.716.9","doi-asserted-by":"publisher","DOI":"10.1007\/s12035-023-03339-2"},{"key":"2025061300350681000_96.7.716.10","doi-asserted-by":"publisher","DOI":"10.1080\/146608200300079536"},{"key":"2025061300350681000_96.7.716.11","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2015-310998"},{"key":"2025061300350681000_96.7.716.12","doi-asserted-by":"publisher","DOI":"10.1002\/mus.28101"},{"key":"2025061300350681000_96.7.716.13","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000001642"},{"key":"2025061300350681000_96.7.716.14","doi-asserted-by":"publisher","DOI":"10.1038\/s41582-019-0265-2"},{"key":"2025061300350681000_96.7.716.15","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2013.491","article-title":"Dysregulated microRNAs in amyotrophic lateral sclerosis microglia modulate genes linked to neuroinflammation","volume":"4","author":"Parisi","year":"2013","journal-title":"Cell Death Dis"},{"key":"2025061300350681000_96.7.716.16","doi-asserted-by":"crossref","DOI":"10.3390\/cells7110219","article-title":"MicroRNAs as Biomarkers in Amyotrophic Lateral Sclerosis","volume":"7","author":"Ricci","year":"2018","journal-title":"Cells"},{"key":"2025061300350681000_96.7.716.17","doi-asserted-by":"publisher","DOI":"10.1016\/j.neurobiolaging.2017.03.027"},{"key":"2025061300350681000_96.7.716.18","doi-asserted-by":"publisher","DOI":"10.1038\/d41573-023-00083-z"},{"key":"2025061300350681000_96.7.716.19","doi-asserted-by":"publisher","DOI":"10.1002\/acn3.50972"},{"key":"2025061300350681000_96.7.716.20","doi-asserted-by":"publisher","DOI":"10.1038\/s41582-023-00891-2"},{"key":"2025061300350681000_96.7.716.21","doi-asserted-by":"publisher","DOI":"10.1080\/21678421.2023.2215838"},{"key":"2025061300350681000_96.7.716.22","doi-asserted-by":"crossref","unstructured":"Banack SA , Dunlop RA , Mehta P , et al . A microRNA diagnostic biomarker for amyotrophic lateral sclerosis. Brain Commun 2024;6. doi:10.1093\/braincomms\/fcae268","DOI":"10.1093\/braincomms\/fcae268"}],"container-title":["Journal of Neurology, Neurosurgery &amp; Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jnnp-2024-335177","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,13]],"date-time":"2025-06-13T07:35:17Z","timestamp":1749800117000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnnp.bmj.com\/lookup\/doi\/10.1136\/jnnp-2024-335177"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,6]]},"references-count":22,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2025,6,12]]},"published-print":{"date-parts":[[2025,7]]}},"alternative-id":["10.1136\/jnnp-2024-335177"],"URL":"https:\/\/doi.org\/10.1136\/jnnp-2024-335177","relation":{},"ISSN":["0022-3050","1468-330X"],"issn-type":[{"value":"0022-3050","type":"print"},{"value":"1468-330X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,6]]}}}